Agentic AI Ignites a New Rally in U.S. Healthcare Stocks

Agentic AI is emerging as a powerful theme in U.S. healthcare stocks, as investors look for companies that use autonomous AI “agents” to streamline clinical and administrative work rather than just generate text. This shift is helping support names tied to AI automation, data workflows, and intelligent assistants across the healthcare value chain.

What “agentic AI” means in healthcare

Agentic AI refers to systems that can plan, sequence, and execute tasks autonomously across multiple software tools, instead of only responding to one‑off prompts. In healthcare, these agents are being deployed for workflows like patient intake, documentation, claims processing, and member support, with human oversight and strong guardrails.

Consulting and industry surveys show that more than 80% of U.S. health systems and health plans now expect agentic AI to deliver meaningful value in areas like clinical operations and revenue cycle management over the next few years. This growing confidence is driving higher investment and is starting to show up in how investors value companies exposed to the theme.

Examples of companies riding the trend

• UiPath Inc. (NYSE: PATH) has launched agentic AI automation solutions for healthcare, designed to handle tasks such as medical records management and claims workflows, and has reinforced this strategy with its acquisition of WorkFusion.
• Other AI‑exposed names highlighted in market commentary around healthcare and agentic AI include SoundHound AI (NASDAQ: SOUN), Evolent Health (NYSE: EVH), and C3.ai (NYSE: AI), which investors view as potential beneficiaries of AI‑driven changes in health services, analytics, and automation.

Research firms estimate that the global agentic AI in healthcare market could grow at a 35–40% rate over the next five years as hospitals and payers seek more personalized care and automated operations. That growth story underpins part of the bullishness around AI‑heavy healthcare and software names.

What investors are watching

Investors following this theme are focusing on:

• Evidence that agentic AI tools actually reduce costs or denial rates, speed up payments, or improve staff productivity in real deployments.
• How quickly companies like UiPath convert healthcare pilots into recurring revenue and larger contracts, versus just announcing new AI features.
• Competitive dynamics as both tech vendors and healthcare‑specific platforms race to embed agentic AI in their products.

The opportunity is significant, but so are execution and valuation risks—especially for smaller or high‑growth names that already price in a lot of AI optimism.